论文部分内容阅读
目的探讨充血性心力衰竭(CHF)患者血浆脑钠素(BNP)水平的变化及培哚普利联合左卡尼汀的干预治疗作用。方法 86例CHF患者给予培哚普利4 mg/d口服,左卡尼汀3 g/d静滴疗程两周。观察用药前后血浆BNP含量的变化及6 min步行距离,同时选择21例同期入院心功能正常者为对照组。结果 CHF患者血浆BNP水平(482±320)pg/ml较对照组(32±8)pg/ml明显增高(P<0.01),CHF组BNP水平升高与心力衰竭程度呈正相关,不同心功能患者血浆BNP水平差异显著,依次为Ⅳ级>Ⅲ级>Ⅱ级(P<0.01),培哚普利联合左卡尼汀治疗后BNP水平明显降低,与治疗前比较差异有统计学意义(P<0.01),6 min步行距离不同程度提高。结论心力衰竭时血浆BNP水平明显增高,培哚普利联合左卡尼汀具有改善心功能的作用。
Objective To investigate the changes of plasma brain natriuretic peptide (BNP) level in patients with congestive heart failure (CHF) and the therapeutic effect of perindopril combined with levocarnitine. Methods 86 patients with CHF were given perindopril 4 mg / d orally, levocarnitine 3 g / d intravenously for two weeks. Before and after treatment to observe changes in plasma BNP levels and 6 min walking distance, while 21 cases of normal cardiac function were selected as control group. Results The plasma BNP level in patients with CHF was significantly higher than that in the control group (482 ± 320 pg / ml, P <0.01). The BNP level in CHF patients was positively correlated with the degree of heart failure. Plasma BNP levels were significantly different, followed by grade Ⅳ> grade Ⅲ> grade Ⅱ (P <0.01). BNP level was significantly lower after perindopril combined with levocarnitine, with statistical significance (P < 0.01), 6 min walking distance increased to varying degrees. Conclusions Plasma BNP level is significantly higher in patients with heart failure. Perindopril combined with levocarnitine has the effect of improving cardiac function.